Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells

Surgery

Volumn 135, Issue 5, 2004, Pages 544-554

  Takabayashi, Tsukasa ^b   Shimizu, Soichi ^b   Clark, Burton D ^b   Beinborn, Martin ^b   Burke, John F ^b   Gelfand, Jeffrey A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; CALCIUM ION; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; MESSENGER RNA;

ARTICLE; BINDING SITE; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 2342455729     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2003.09.010     Document Type: Article

References (39)

1. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
2. Wogensen L, Jensen M, Svensson P, Worsaae H, Welinder B, Nerup J. Pancreatic beta-cell function and interleukin-1β in plasma during the acute phase response in patients with major burn injuries. Eur J Clin Invest 1993;23:311-9.
3. Shito M, Wakabayashi G, Ueda M, Shimazu M, Shirasugi N, Endo M, et al. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 1997;63:143-8.
4. Haeffner-Cavaillon N, Roussellier N, Ponzio O, Carreno M-P, Laude M, Carpentier A, et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;98:1100-6.
5. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
6. Bengtson A, Heideman M. Anaphylatoxin formation in sepsis. Arch Surg 1988;123:645-9.
7. Gelfand JA, Donelan M, Hawiger A, Burke JF. Alternative complement pathway activation increases mortality in a model of burn injury in mice. J Clin Invest 1982;70:1170-6.
8. Pfeifer PH, Brems JJ, Brunson M, Hugli TE. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. Immunopharmacology 2000;46:163-74.
9. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
10. Goldstein IM. Complement: biologically active products. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. 2nd ed. New York: Raven Press; 1992. p. 63-80.
11. Rollins TE, Springer MS. Identification of the polymorphonuclear leukocyte C5a receptor. J Biol Chem 1985;260:7157-60.
12. 125I-C3a binding. Biochemistry 1992;31:11274-82.
13. Elsner J, Oppermann M, Czech W, Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 1994;83:3324-31.
14. Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, et al. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518-22.
15. Daffern PJ, Pfeifer PH, Ember JA, Hugli TE. C3a is a chemotaxin for human eosinophils but not for neutrophils: I, C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995;181:2119-27.
16. Bischoff SC, DeWeck AL, Dahinden CA. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA 1990;87:6813-7.
17. Kurimoto Y, de Weck AL, Dahinden CA. Interleukin 3-dependent mediator release in basophils triggered by C5a. J Exp Med 1989;170:467-79.
18. Kretzschmar T, Jeromin A, Gietz C, Bautsch W, Klos A, Kohl J, et al. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur J Immunol 1993;23:558-61.
19. Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, et al. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996;157:1693-8.
20. Roglic A, Prossnitz ER, Cavanagh SL, Pan Z, Zou A, Ye RD. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim Biophys Acta 1996;1305:39-43.
21. Boulay F, Mery L, Tardif M, Brouchon L, Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 1991;30:2993-9.
22. Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J, et al. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 1996;26:1944-50.
23. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614-7.
24. Zwirner J, Gotze O, Begemann G, Kapp A, Kirchhoff K, Werfel T. Evaluation of C3a receptor expression on human leukocytes by the use of novel monoclonal antibodies. Immunology 1999;97:166-72.
25. Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor translational signal provided by lipopolysaccharide or IL-1 itself. Blood 1990;76:1631-8.
26. Takabayashi T, Vannier E, Clark BD, Margolis NM, Dinarello CA, Burke JF, et al. A new biologic role for C3a and C3a desArg: regulation of tumor necrosis factor α and interleukin-1β synthesis. J Immunol 1996;156:3455-60.
27. Loms Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmuller G. Establishment of a human cell line (MONO MAC 6) with characteristics of mature monocytes. Int J Cancer 1988;41:456-61.
28. Hunter WM, Greenwood FC. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 1962;194:495-6.
29. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
30. Burg M, Martin U, Rheinheimer C, Kohl J, Bautsch W, Bottger EC, et al. IFN-γ up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells and related cell lines. J Immunol 1995;155:4419-26.
31. McColl SR, Beauseigle D, Gilbert C, Naccache PH. Priming of the human neutrophil respiratory burst by granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α involves regulation at a post-cell surface receptor level. J Immunol 1990;145:3047-53.
32. Burg M, Martin U, Bock D, Rheinheimer C, Kohl J, Bautsch W, et al. Differential regulation of the C3a and C5a receptors (CD88) by INF-γ and PMA in U937 cells and related myeloblastic cell lines. J Immunol 1996;157:5574-81.
33. Lee CH, Katz A, Simon MI. Multiple regions of G alpha 16 contribute to the specificity of activation by the C5a receptor. Mol Pharmacol 1995;47:218-23.
34. Fisher CJ Jr, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trials. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-43.
35. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
36. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-11.
37. Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study Group. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225-31.
38. Harada H, Wakabayashi G, Takayanagi A, Shimazu M, Matsumoto K, Obara H, et al. Transfer of the interleukin-1 receptor antagonist gene into rat liver abrogates hepatic ischemia-reperfusion injury. Transplantation 2002;74:1434-41.
39. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, et al. Protective effects of C5a blockade in sepsis. Nat Med 1999;5:788-92.